CD4+ T cells sustain aggressive chronic lymphocytic leukemia in Eμ-TCL1 mice through a CD40L-independent mechanism.

Chronic lymphocytic leukemia (CLL) is caused by the progressive accumulation of mature CD5+ B cells in secondary lymphoid organs. In vitro data suggest that CD4+ T lymphocytes also sustain survival and proliferation of CLL clones through CD40L/CD40 interactions. In vivo data in animal models are conflicting. To clarify this clinically relevant biological issue, we generated genetically modified Eμ-TCL1 mice lacking CD4+ T cells (TCL1+/+AB0), CD40 (TCL1+/+CD40-/-), or CD8+ T cells (TCL1+/+TAP-/-), and we monitored the appearance and progression of a disease that mimics aggressive human CLL by flow cytometry and immunohistochemical analyses. Findings were confirmed by adoptive transfer of leukemic cells into mice lacking CD4+ T cells or CD40L or mice treated with antibodies depleting CD4 T cells or blocking CD40L/CD40 interactions. CLL clones did not proliferate in mice lacking or depleted of CD4+ T cells, thus confirming that CD4+ T cells are essential for CLL development. By contrast, CD8+ T cells exerted an antitumor activity, as indicated by the accelerated disease progression in TCL1+/+TAP-/- mice. Antigen specificity of CD4+ T cells was marginal for CLL development, because CLL clones efficiently proliferated in transgenic mice whose CD4 T cells had a T-cell receptor with CLL-unrelated specificities. Leukemic clones also proliferated when transferred into wild-type mice treated with monoclonal antibodies blocking CD40 or into CD40L-/- mice, and TCL1+/+CD40-/- mice developed frank CLL. Our data demonstrate that CD8+ T cells restrain CLL progression, whereas CD4+ T cells support the growth of leukemic clones in TCL1 mice through CD40-independent and apparently noncognate mechanisms.

[1]  Emanuela M. Ghia,et al.  Wnt5a enhances proliferation of chronic lymphocytic leukemia and ERK1/2 phosphorylation via a ROR1/DOCK2-dependent mechanism , 2020, Leukemia.

[2]  M. Seiffert,et al.  T-cells in chronic lymphocytic leukemia: Guardians or drivers of disease? , 2020, Leukemia.

[3]  D. Colomer,et al.  TBET‐expressing Th1 CD4+ T cells accumulate in chronic lymphocytic leukaemia without affecting disease progression in Eµ‐TCL1 mice , 2019, British journal of haematology.

[4]  Emanuela M. Ghia,et al.  Cirmtuzumab Blocks Wnt5a/ROR1-Stimulation Of NF-κB To Repress Autocrine STAT3-Activation In Chronic Lymphocytic Leukemia. , 2019, Blood.

[5]  F. Bosch,et al.  Chronic lymphocytic leukaemia: from genetics to treatment , 2019, Nature Reviews Clinical Oncology.

[6]  L. Rassenti,et al.  Wnt5a causes ROR1 to complex and activate cortactin to enhance migration of chronic lymphocytic leukemia cells , 2018, Leukemia.

[7]  E. Campo,et al.  Control of chronic lymphocytic leukemia development by clonally-expanded CD8+ T-cells that undergo functional exhaustion in secondary lymphoid tissues , 2018, Leukemia.

[8]  A. Langerak,et al.  Identification of Distinct Unmutated Chronic Lymphocytic Leukemia Subsets in Mice Based on Their T Cell Dependency , 2018, Front. Immunol..

[9]  S. Iacovelli,et al.  Pathogen‐specific B‐cell receptors drive chronic lymphocytic leukemia by light‐chain‐dependent cross‐reaction with autoantigens , 2017, EMBO molecular medicine.

[10]  K. Stamatopoulos,et al.  Restrictions in the T-cell repertoire of chronic lymphocytic leukemia: high-throughput immunoprofiling supports selection by shared antigenic elements , 2017, Leukemia.

[11]  G. Lenz,et al.  Splenic Marginal Zone Granulocytes Acquire an Accentuated Neutrophil B-Cell Helper Phenotype in Chronic Lymphocytic Leukemia. , 2016, Cancer research.

[12]  C. Klein,et al.  Targeting Macrophages Sensitizes Chronic Lymphocytic Leukemia to Apoptosis and Inhibits Disease Progression. , 2016, Cell reports.

[13]  G. Widhopf,et al.  Wnt5a induces ROR1/ROR2 heterooligomerization to enhance leukemia chemotaxis and proliferation. , 2015, The Journal of clinical investigation.

[14]  R. Greil,et al.  CD4+ T cells, but not non-classical monocytes, are dispensable for the development of chronic lymphocytic leukemia in the TCL1-tg murine model , 2015, Leukemia.

[15]  M. Colombo,et al.  Stromal niche communalities underscore the contribution of the matricellular protein SPARC to B-cell development and lymphoid malignancies , 2014, Oncoimmunology.

[16]  E. Remmerswaal,et al.  IL-21 and CD40L signals from autologous T cells can induce antigen-independent proliferation of CLL cells. , 2013, Blood.

[17]  Keith M. Thompson,et al.  Chronic lymphocytic leukemia cells are activated and proliferate in response to specific T helper cells. , 2013, Cell reports.

[18]  Sophia Yancopoulos,et al.  Autoantigen can promote progression to a more aggressive TCL1 leukemia by selecting variants with enhanced B-cell receptor signaling , 2013, Proceedings of the National Academy of Sciences.

[19]  J. Gribben,et al.  T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production. , 2013, Blood.

[20]  J. Leonard,et al.  Stromal Endothelial Cells Establish a Bidirectional Crosstalk with Chronic Lymphocytic Leukemia Cells through the TNF-Related Factors BAFF, APRIL, and CD40L , 2012, The Journal of Immunology.

[21]  Kostas Stamatopoulos,et al.  Stereotyped B-cell receptors in one-third of chronic lymphocytic leukemia: a molecular classification with implications for targeted therapies. , 2012, Blood.

[22]  M. Muzio,et al.  The functional in vitro response to CD40 ligation reflects a different clinical outcome in patients with chronic lymphocytic leukemia , 2011, Leukemia.

[23]  Annette Lee,et al.  A novel adoptive transfer model of chronic lymphocytic leukemia suggests a key role for T lymphocytes in the disease. , 2011, Blood.

[24]  John Quackenbush,et al.  Eμ-TCL1 mice represent a model for immunotherapeutic reversal of chronic lymphocytic leukemia-induced T-cell dysfunction , 2009, Proceedings of the National Academy of Sciences.

[25]  E. Meffre,et al.  Chronic Lymphocytic Leukemia Cells Recognize Conserved Epitopes Associated with Apoptosis and Oxidation , 2008, Molecular medicine.

[26]  P. Ghia,et al.  Novel insights in chronic lymphocytic leukemia: are we getting closer to understanding the pathogenesis of the disease? , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  J. Byrd,et al.  Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. , 2008, The Journal of clinical investigation.

[28]  R. Rosenquist,et al.  A new perspective: molecular motifs on oxidized LDL, apoptotic cells, and bacteria are targets for chronic lymphocytic leukemia antibodies. , 2008, Blood.

[29]  T. Kipps,et al.  BAFF and APRIL support chronic lymphocytic leukemia B-cell survival through activation of the canonical NF-kappaB pathway. , 2007, Blood.

[30]  C. Croce,et al.  B cell receptors in TCL1 transgenic mice resemble those of aggressive, treatment-resistant human chronic lymphocytic leukemia. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[31]  M. Gobbi,et al.  Interleukin-21 receptor (IL-21R) is up-regulated by CD40 triggering and mediates proapoptotic signals in chronic lymphocytic leukemia B cells. , 2006, Blood.

[32]  J. Gribben,et al.  Chronic lymphocytic leukemia cells induce changes in gene expression of CD4 and CD8 T cells. , 2005, The Journal of clinical investigation.

[33]  E. Meffre,et al.  Unmutated and mutated chronic lymphocytic leukemias derive from self-reactive B cell precursors despite expressing different antibody reactivity. , 2005, The Journal of clinical investigation.

[34]  C. Croce,et al.  Human chronic lymphocytic leukemia modeled in mouse by targeted TCL1 expression , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[35]  F. Sallusto,et al.  Chronic lymphocytic leukemia B cells are endowed with the capacity to attract CD4+, CD40L+ T cells by producing CCL22 , 2002, European journal of immunology.

[36]  Y. Zhan,et al.  Prolonged allograft survival in anti-CD4 antibody transgenic mice: lack of residual helper T cells compared with other CD4-deficient mice. , 2000, Transplantation.

[37]  E. Rogaev,et al.  Association between angiotensin-converting enzyme and Alzheimer disease. , 2000, Archives of neurology.

[38]  N. Chiorazzi,et al.  Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. , 1999, Blood.

[39]  H. Pircher,et al.  Qualitative and quantitative requirements for CD4+ T cell-mediated antiviral protection. , 1999, Journal of immunology.

[40]  M. Schuler,et al.  Direct cellular interaction with activated CD4(+) T cells overcomes hyporesponsiveness of B-cell chronic lymphocytic leukemia in vitro. , 1998, Cellular immunology.

[41]  W. Heath,et al.  Defective TCR expression in transgenic mice constructed using cDNA‐based α‐ and β‐chain genes under the control of heterologous regulatory elements , 1998, Immunology and cell biology.

[42]  T. Kipps,et al.  Acquired CD40-ligand deficiency in chronic lymphocytic leukemia , 1997, Nature Medicine.

[43]  D. Oscier,et al.  Differential rates of somatic hypermutation in V(H) genes among subsets of chronic lymphocytic leukemia defined by chromosomal abnormalities. , 1997, Blood.

[44]  J. Ceuppens,et al.  CD40 triggering of chronic lymphocytic leukemia B cells results in efficient alloantigen presentation and cytotoxic T lymphocyte induction by up-regulation of CD80 and CD86 costimulatory molecules , 1997, Leukemia.

[45]  P. Borrow,et al.  CD40L-deficient mice show deficits in antiviral immunity and have an impaired memory CD8+ CTL response , 1996, The Journal of experimental medicine.

[46]  F. Rodeghiero,et al.  Interleukin-15 promotes the growth of leukemic cells of patients with B-cell chronic lymphoproliferative disorders. , 1996, Blood.

[47]  R J Armitage,et al.  Humoral immune responses in CD40 ligand-deficient mice , 1994, The Journal of experimental medicine.

[48]  N. Yoshida,et al.  The immune responses in CD40-deficient mice: impaired immunoglobulin class switching and germinal center formation. , 1994, Immunity.

[49]  T. Kipps,et al.  Activated T cells induce expression of B7/BB1 on normal or leukemic B cells through a CD40-dependent signal , 1993, The Journal of experimental medicine.

[50]  D. Campana,et al.  Interferon gamma inhibits apoptotic cell death in B cell chronic lymphocytic leukemia , 1993, The Journal of experimental medicine.

[51]  S. Tonegawa,et al.  TAP1 mutant mice are deficient in antigen presentation, surface class I molecules, and CD4−8+ T cells , 1992, Cell.

[52]  G. Delespesse,et al.  Interleukin 4 protects chronic lymphocytic leukemic B cells from death by apoptosis and upregulates Bcl-2 expression , 1992, The Journal of experimental medicine.

[53]  D. Gray,et al.  Mice lacking MHC class II molecules , 1991, Cell.

[54]  I. Touw,et al.  The proliferative response of B cell chronic lymphocytic leukemia to interleukin 2: functional characterization of the interleukin 2 membrane receptors. , 1987, Blood.

[55]  N. Chiorazzi,et al.  mechanisms of disease Chronic Lymphocytic Leukemia , 2010 .

[56]  L. Lagneaux,et al.  Chronic lymphocytic leukemic B cells but not normal B cells are rescued from apoptosis by contact with normal bone marrow stromal cells. , 1998, Blood.